THE LOCAL TREATMENT OF BURNS WITH ANTIBIOTICS

Napoli B., D’Arpa N., Masellis A., Masellis M.

Plastic Surgery and Burns Therapy Operating Unit, ARNAS Civic Hospital, Palermo, Italy

SUMMARY. After presenting an analysis of the principal antiseptics used for the local treatment of burns, highlighting their toxicity and the limitations of their antibacterial effectiveness, we describe the therapeutic protocol used in our burns centre (where antibacterial treatment consists exclusively of antibiotics for both local and systemic use). We review the data regarding actual and of the considerable selection caused by routine use of mafenide acetate.

The history of the use of silver as an antiseptic in the treatment of burns since the mid-1960s until the present day is emblematic.

- Moyer, 1965 - silver nitrate (0.5% solution). We list below the main aspects of this solution:
  1. Physiological (isotonic) solution cannot be used in the preparation as this would cause precipitation of silver chloride. However, distilled water makes 0.5% silver nitrate solution extremely hypotonic. This hypotonia causes the absorption of a large volume of water and the loss of sodium, chlorine, and potassium. The result is a marked hydroelectrolytic imbalance.
  2. Many Gram-negative bacteria can reduce nitrate into nitrite, the absorption of which can occasionally cause methemoglobinemia. The last case caused by silver nitrate dates back to 1968, although one new case has in fact been reported.
  3. The medication covering the lesion must be moistened every 3-4 h and changed twice a day, which increases mechanical trauma for the patient and the nursing time. It would seem however that the effects on the reduction of the infections are due more to the frequent change in medication and the high level of cleanliness using this technique than to the actual use of silver.

- Fox, 1968 - silver sulphadiazine (2% cream). The main features of this antiseptic can be summarized as follows:
  1. It is not to be used in patients with a G6PD deficit in whom the sulphamide component can cause haemolytic anaemia.
  2. It is not to be used in patients who are sensitive

The toxicity and limitations of the antibacterial effectiveness of antiseptics

The debate on the use of antiseptics or antibiotics in the local antibacterial treatment of burns is still open. In general, it is believed that antibiotics are responsible for the selection of resistant strains, while the same cannot be said of antiseptics when both antibiotics and antiseptics are applied to lesions in insufficient concentrations. The current literature offers many studies on the toxicity and the limitations of the antimicrobial effectiveness of the principal antiseptics used until the present day.

For example, we know that in burns covering more than 20% of the total body surface area (TBSA), povidone iodine interferes with thyroid function and may cause metabolic acidosis owing to kidney poisoning, which can even be fatal. In addition, it cannot be used on “secreting” burns, since - being inhibited by organic substances (including blood) - it loses its antibacterial effectiveness. It may also not be active against “epidemic” methicillin-resistant Staphylococci aurei (E-MRSA) and Pseudomonas, as it is subject, among other things, to contamination by opportunistic pathogens of the Pseudomonadaceae family (Burkholderia Cepacia, formerly known as Pseudomonas Cepacia).

With regard to mafenide acetate, we know that the inhibition of carbonic anhydrase that it causes at the level of the renal tubules leads to excretion of bicarbonate and chlorine, with consequent metabolic acidosis and compensatory hyperventilation. In the late 1970s higher mortality was reported in relation to respiratory complications following treatment of burns in over 30% TBSA. In the early 1970s descriptions began to appear of superinfections, due especially to Providencia Stuartii (Enterobacteriaceae), that were resistant to treatment with antibiotics. Superinfections caused by fungi were also observed. According to Monafo, these superinfections were the result
to metals, in whom silver can cause allergic reactions.\textsuperscript{10} There have been reports of medullary toxicity levels high enough to lead to temporary but severe leukopenia.\textsuperscript{11}

4. As long ago as 1980 it was believed to be responsible for plasmidic resistance to Enterobacteriaceae;\textsuperscript{2} in the same years (1978-85), plasmidic-type resistance to antibiotics following routine use was also found in strains of \textit{Pseudomonas aeruginosa}.\textsuperscript{8}

5. It causes the formation of a moist, macerated, non-uniform eschar that promotes bacterial colonization in extensive burns and is difficult to treat surgically.\textsuperscript{4}

- \textbf{Monafo, 1976 - silver sulphadiazine (1\%) + cerium nitrates (2.2\%)}
  
  As silver sulphadiazine offered insufficient protection against the growth of Gram-positive bacteria in patients with extensive burns, a combination was introduced with cerium nitrate (a rare earth metal), in the belief that together the two substances might have a synergistic effect.\textsuperscript{13} The results in the literature, however, are not consistent but contradictory, both \textit{in vitro} and \textit{in vivo}.\textsuperscript{4,12,14} One of the advantages is thought to be the hardening of the eschar due to the precipitation of calcium carbonate and phosphate caused by cerium. The calcification of the eschar would block bacterial colonization and also permit a long delay (8-12 weeks) before proceeding to surgery.\textsuperscript{11} But who is willing to wait all this time before operating on a major burns victim?

- \textbf{Slow release silver (Acquacel Ag; Acticoat)}
  
  Currently it is believed that silver, in the ionic form used in former formulations (Ag\textsuperscript{+}), is deactivated by the organic fluids in the lesions and must therefore be frequently replaced. Thus, it is the constant replacement through frequent medications that ensures its effectiveness. The new formulations, in which silver is present in either ionic (Acquacel Ag) or nanocrystalline form, allow further release of silver when this is used up in the interaction with the lesion. The continuous release of silver makes it possible to leave the medication \textit{in situ} for a few days (3 to 7), with decreased mechanical trauma for the patient and decreased nursing time. However, these procedures make it more difficult to inspect the lesion.\textsuperscript{18} Antibacterial activity towards E-MRSA, \textit{Pseudomonas aeruginosa}, and \textit{Staphylococcus aureus} has been reported.\textsuperscript{1} It is however too early to assess the effect on bacterial resistance, in view of its current non-routine use - the first study on the bacterial resistance caused by silver sulphadiazine appeared at least ten years after it began to be used, and for at least four years no such phenomena were reported.\textsuperscript{8}

**Local treatment of burns with antibiotics**

Our protocol for the local treatment of burns consists of bathing in running water with debridement (on hospitalization, frequently during the course of the disease, and before surgery) and successive medication with antibiotics for topical or systemic use. With regard to partial-thickness burns, the most frequently used routine treatments are with gentamicin, rifamycin S.V., and the chloramphenicol-collagenase association. A multi-centre study (conducted in 11 Italian burn centres) in the years 1992-1993, published in 1994,\textsuperscript{12} highlighted chloramphenicol’s absolute lack of antibacterial activity, meaning that when chloramphenicol is associated with collagenase it adds nothing to the latter’s activity (enzymatic debridement). Conversely, both gentamicin (which we use for brief periods and for exposed face burn treatment) and rifamycin S.V. (also used for brief periods and as a compress) maintain good antibacterial activity. Now, ten years after the above-mentioned study, a new multi-centre study would be very useful.

In full-thickness burns with necrotic eschar in elderly or diabetic patients, or when the location of the burn, its extent, and the patient’s general conditions are so compromised that surgical escharectomy is risky, we use salicylate Vaseline in various concentrations (5-20\%), impregnated with antibiotics, applied through incisions in the eschar itself to facilitate penetration both in and under it. The initial choice of which antibiotic to add to the salicylate Vaseline for a specific patient is made on the basis of the results of the antibiograms carried out on germs isolated from the burns of patients hospitalized in the immediately previous period. Subsequently, the antibiotic can be used to which any germs isolated from the patient are sensitive.\textsuperscript{18,19}

In full-thickness burns with granulating surfaces, before or during completion of surgical therapy, we use a fatty antibiotic-impregnated gauze as a compress, in relation to the antibiogram. During the process of becoming chronic, when there are limited residual areas of de-epithelialization and/or infected granulation (generally by \textit{Staphylococcus aureus}), these are treated with polyurethane foam (which associates debriding action with absorption of burn secretions) and with the antibiotic to which the germ has proved sensitive. As a final point, a gradual and predetermined release system has been devised that guarantees an antibiotic concentration which maintains aseptic conditions for five days following a single administration associated with keratinocyte sheets. The antibiotic we used,
applied on a polymer coated with a drug-permeable membrane, was vancomycin, which thus proved to be non-toxic to cultured keratinocytes.20,21

Analysis of burn patient data in the period 2000-2003

Our analysis regarded patients of all ages and burned body surface areas hospitalized in our burns centre during the period 2000-2003.

Table I presents the cases of septicaemia (in parentheses) as well as the total number of patients distributed by age and burn extent.

Table I - Distribution by extent/age in burn patients hospitalized in 2000-2003

<table>
<thead>
<tr>
<th>Extent (TBSA)</th>
<th>Age (yr)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;15%</td>
<td>0-14</td>
<td>15-64</td>
</tr>
<tr>
<td>15-50%</td>
<td>292 (1)</td>
<td>35</td>
</tr>
<tr>
<td>50%</td>
<td>37 (4)</td>
<td>108 (23)</td>
</tr>
<tr>
<td>Total</td>
<td>335 (9)</td>
<td>470 (31)</td>
</tr>
</tbody>
</table>

Septicaemia cases given in parentheses.

As can be seen, the number of cases of septicaemia - as might be expected - increased in relation to the extent of the burn.

In particular, in the group of burns between 15 and 50% TBSA, the average burn surface was 35% (SD ± 10). Although the septicaemia rate (0.26%) in the group of patients with burns in less than 15% TBSA was predictably very low, about 40% of such patients were treated surgically because their burns, though limited in area, involved a higher risk of infection, as they were deep and subject to more intense manipulation (Table II).

Table II - Burns in <15% TBSA - distribution by surgical treatment

<table>
<thead>
<tr>
<th>Cases of septicaemia</th>
<th>Number operated on</th>
<th>Number not operated on</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>305</td>
<td>442</td>
<td>747</td>
</tr>
</tbody>
</table>

The patients subjected to surgery included many with pathologies favouring infection who presented a dual risk - there were altogether 64 of these immunodepressed patients (8.5%) (Table III).

The main germs isolated from the blood cultures were, as might have been expected, Staphylococcus aureus and Pseudomonas aeruginosa (Table IV), accompanied by other Gram-positive (Table V) and Gram-negative (Table VI) germs, generally opportunistic pathogens, in cases of septicaemia that in the majority of cases were polymicrobial.

Table III - Burns in <15% TBSA - distribution by pathologies with infective risk

<table>
<thead>
<tr>
<th>Pathology</th>
<th>Number of patients</th>
<th>Number of patients operated on</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant neoplasm</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Drug use, HIV positive, alcoholism</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Respiratory and/or inhalation pathology</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Hepatic cirrhosis</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Anorexia</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Chronic liver failure in diabetes</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Patients on steroids</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Diabetes</td>
<td>33</td>
<td>16</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>10</td>
<td>9</td>
</tr>
<tr>
<td>Total</td>
<td>64</td>
<td>37</td>
</tr>
</tbody>
</table>

Table IV - Germs isolated from blood cultures

<table>
<thead>
<tr>
<th>Staphylococcus aureus</th>
<th>35</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>18</td>
</tr>
</tbody>
</table>

Table V - Other Gram-positive germs isolated

<table>
<thead>
<tr>
<th>Staphylococcus epidermidis</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staphylococcus haemolyticus</td>
<td>4</td>
</tr>
<tr>
<td>Enterococcus faecalis</td>
<td>4</td>
</tr>
<tr>
<td>Enterococcus faecium</td>
<td>2</td>
</tr>
<tr>
<td>Streptococcus pyogenes</td>
<td>2</td>
</tr>
<tr>
<td>Corynebacterium</td>
<td>1</td>
</tr>
</tbody>
</table>

Table VI - Other Gram-negative germs isolated

<table>
<thead>
<tr>
<th>Acinetobacter baumanii</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acinetobacter haemolyticus</td>
<td>2</td>
</tr>
<tr>
<td>Alcaligenes xylosoxidans</td>
<td>2</td>
</tr>
<tr>
<td>Enterobacteriaceae:</td>
<td></td>
</tr>
<tr>
<td>E. coli</td>
<td>4</td>
</tr>
<tr>
<td>Proteus mirabilis</td>
<td>3</td>
</tr>
<tr>
<td>Serratia marcescens</td>
<td>2</td>
</tr>
<tr>
<td>Enterobacter cloacae</td>
<td>2</td>
</tr>
<tr>
<td>Providencia stuartii</td>
<td>2</td>
</tr>
<tr>
<td>Morganella morganii</td>
<td>1</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>1</td>
</tr>
</tbody>
</table>

Table VII shows the distribution of deaths in relation to age and all burn percentages, with a comparison to predicted mortality (Probit analysis). As can be seen, the best results were obtained in the group of patients over 65 years old, with a reduction in the death rate of about 50%. Good results were also obtained in other age groups.22 To conclude (Table VIII), while not all deaths were caused by septicaemia, not all septicaemic patients died - among our
cases septicaemia was not in fact the leading cause of death.

Conclusion

After bacterial colonization, infection, and sepsis of the burn area, septicaemia is the severest form of infection arising from contamination of a burn. This contamination, whether originating from the patient (skin, faeces, oropharynx, 16%) or from the environment, medical personnel, or other patients (84%), can be counteracted only by using various means at the same time. The principal means are the sterility of the environment and of the medications, the strengthening of the organism’s defence mechanisms, and surgical coverage of the burn surface. Among these remedies, pharmacological anti-infective treatment clearly plays an important role. This must make use of non-toxic material possessing an antibacterial effect that targets the micro-organism in question, in non-fluctuating concentrations at the level of the lesion and capable of encouraging selection of resistant micro-organisms. The analysis of the main antiseptics in use and the results we obtained as regards general mortality and secondary mortality due to septicaemia provide evidence of the advisability of continuing to use antibiotics in the local treatment of burns.


BIBLIOGRAPHY


Table VII - Distribution in relation to death

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Number of patients</th>
<th>Number of deaths</th>
<th>Expected number of deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-11</td>
<td>35</td>
<td>4</td>
<td>3.5</td>
</tr>
<tr>
<td>1-64</td>
<td>170</td>
<td>20</td>
<td>21.4</td>
</tr>
<tr>
<td>&gt;65</td>
<td>114</td>
<td>18</td>
<td>37.1</td>
</tr>
</tbody>
</table>

* Poisson analysis

Table VIII - Septicaemia as a cause of death

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Number of patients</th>
<th>Number of cases of NEC-dots</th>
<th>Deaths due to septicaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-11</td>
<td>335</td>
<td>9</td>
<td>2.22%</td>
</tr>
<tr>
<td>1-64</td>
<td>170</td>
<td>31</td>
<td>6.19%</td>
</tr>
<tr>
<td>&gt;65</td>
<td>111</td>
<td>6</td>
<td>2.33%</td>
</tr>
</tbody>
</table>


This paper was received on 10 November 2004

Address correspondence to: Dr B. Napoli, Unità Operativa di Chirurgia e Terapia delle Ustioni, Ospedale Civico ARNAS, Via C. Lazzaro 58, Palermo, Italy. Tel. 091 6663631; fax: 091 596404; e-mail: mbcpa@medbc.com

G. WHITAKER INTERNATIONAL BURNS PRIZE – PALERMO (Italy)
Under the patronage of the Authorities of the Sicilian Region for 2007

By law n. 57 of June 14th 1983 the Sicilian Regional Assembly authorized the President of the Region to grant the “Giuseppe Whitaker Foundation”, a non-profit-making organisation under the patronage of the Accademia dei Lincei with seat in Palermo, a contribution for the establishment of the annual G. Whitaker International Burns Prize aimed at recognising the activity of the most qualified experts from all countries in the field of burns pathology and treatment.

Law n. 23 of December 2002 establishes that the prize becomes biannual.

The next prize will be awarded in 2005 by the month of October in Palermo at the seat of the G. Whitaker Foundation.

The amount of the prize is fixed at Euro 20,660.00.

The Adjudicating Committee is composed of the President of the Foundation, the President of the Sicilian Region, the Representative of the National Lincei Academy within the G. Whitaker Foundation, the Dean of the Faculty of Medicine and Surgery of Palermo University or his nominee, a Representative of the Italian Society of Plastic Surgery, three experts in the field of prevention, pathology, therapy and functional recovery of burns, the winner of the prize awarded in the previous year and a legal expert nominated in agreement with the President of the Region as a guarantee of the respect for the scientific purpose which the legislators intended to achieve when establishing the prize.

Anyone who considers himself/herself to be qualified to compete for the award may send by January 31st 2007 a detailed curriculum vitae to: Michele Masellis M.D., Secretary-Member of the Scientific Committee, G. Whitaker Foundation, Via Dante 167, 90141 Palermo, Italy.